Efficacy of post-lenvatinib treatments in patients (pts) with advanced renal cell carcinoma (aRCC).
Justine Panian(University of California San Diego), Rana R. McKay(University of California San Diego), Caiwei Zhong(Dana-Farber Cancer Institute), Roxanne Quinn(University of California San Diego), Aly‐Khan A. Lalani(Juravinski Cancer Centre), Ravindran Kanesvaran(University of Ioannina), Ben Tran(The Royal Melbourne Hospital), Sumanta K. Pal(City of Hope), Andrew Weickhardt(Austin Hospital), Renée Maria Saliby(Yale University), Toni K. Choueiri(Harvard University), Carmel Malvar(University of California San Diego), Hedyeh Ebrahimi(Beth Israel Deaconess Medical Center), Sharon Choi(University of California San Diego), Guillermo de Velasco(Dana-Farber Cancer Institute), Cristina Suárez(Vall d'Hebron Hospital Universitari), Evan Ferrier, Martín Zarbá(University of Calgary), Daniel Yick Chin Heng(University of Calgary), Eddy Saad(Dana-Farber Cancer Institute)
Cited by 2
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k